资讯

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
pharmaphorum12 小时
Akeso PD-1 inhibitor cleared as Keytruda challenger advances
Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...
Fierce Pharma13 小时
Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout
Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...
Le Lézard1 小时
Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...